Specialty medicines • Bangladesh

Tyzepa (Tirzepatide)

Product Name : Tyzepa
Generic Name : Tirzepatide
Formulation : Subcutaneous Injection (Pre-filled Syringe)
Available Pack Size : 1 Pre-filled Syringe per box
Available Strengths : 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
Manufacturer : Drug International
Country Of Origin : Bangladesh

SKU tirzepatide-tyzepa Categories , Brand:

Confirm your order

Speak with our team about your prescribed strength, pack size, price and delivery.
Use medicines only as prescribed by your clinician.

Description

Tyzepa (Tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, a once-weekly subcutaneous injectable twincretin that simultaneously activates the GIP receptor (GIPR) with potency comparable to native GIP and the GLP-1 receptor (GLP-1R) to potentiate glucose-dependent insulin secretion from pancreatic beta cells, suppress inappropriate glucagon release from pancreatic alpha cells, slow gastric emptying to attenuate postprandial glucose excursions, and engage central satiety circuits in the hypothalamus, producing clinically meaningful reductions in both HbA1c and body weight that exceed those of any previously approved incretin-based agent.

 

Supplied as a subcutaneous injection in a pre-filled syringe, 1 pre-filled syringe per box, and available in the complete six-strength escalation range of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg covering the full approved tirzepatide dose ladder from tolerability initiation through maximum therapeutic dose manufactured by Drug International Ltd., Bangladesh. Its active ingredient, tirzepatide INN, is a 39-amino acid acylated peptide with structural homology to native GIP, engineered to bind and activate both GIPR and GLP-1R within a single molecular entity, the first approved dual incretin receptor agonist (twincretin) in the antidiabetic drug class, structurally and mechanistically distinct from monoagonist GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide) that activate only the GLP-1 receptor.

 

The co-activation of GIPR by tirzepatide augments the GLP-1R-mediated glycemic and weight effects by engaging adipose tissue GIP receptors involved in lipid partitioning and by potentiating pancreatic beta cell responsiveness through synergistic cyclic adenosine monophosphate (cAMP) signaling from both receptor pathways simultaneously. In the pivotal SURPASS-1 monotherapy trial (478 patients, 40 weeks), tirzepatide 5 mg achieved a mean HbA1c reduction of 1.87% from baseline versus 0.04% with placebo, with 87.4% of patients achieving HbA1c below 7.0% versus 19.9% with placebo, without hypoglycemia as monotherapy; tirzepatide at higher dose steps (7.5 mg through 15 mg) delivers incrementally greater HbA1c and body weight reductions for patients requiring additional glycemic intensification.

 

In the SURPASS-2 head-to-head trial versus semaglutide 1 mg (1,879 patients, 40 weeks), tirzepatide demonstrated statistically significant superiority in both HbA1c reduction and body weight reduction at all doses studied, establishing tirzepatide as the most efficacious approved injectable antidiabetic agent studied against an active comparator in a prospective randomized trial. Searching for Tyzepa Tirzepatide? Mediaid Pharmacy lists this product across its diabetes medicines and Tirzepatide Medicines portfolios and ships it worldwide.

Basic Product Information of Tyzepa (Tirzepatide)

Brand Name Tyzepa (Tirzepatide)
Product Name Tyzepa
Generic Name Tirzepatide INN
Drug Class Dual GIP/GLP-1 Receptor Agonist; Twincretin; Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonist; Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist; Dual Incretin Receptor Agonist; Once-Weekly Subcutaneous Injectable Antidiabetic Agent; Incretin Mimetic; Glucose-Dependent Insulin Secretion Potentiator; Glucagon Suppressor; Cardiometabolic Agent; Antiobesity Agent (Adjunct in T2DM)
Formulation Subcutaneous Injection (Pre-filled Syringe)
Available Strengths 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg tirzepatide per pre-filled syringe  the complete six-step approved dose escalation range, from tolerability initiation through the maximum approved maintenance dose
Available Pack Size 1 pre-filled syringe per box
Recommended Dose & Administration Initiation dose (Weeks 1–4): 2.5 mg subcutaneously once weekly. This is a tolerability initiation dose, not a therapeutic maintenance dose; it minimizes nausea and gastrointestinal adverse effects during treatment commencement. Step 1 therapeutic (Week 5 onward): Increase to 5 mg subcutaneously once weekly after completing 4 weeks at 2.5 mg. Step 2 (if additional glycemic control required): Increase to 7.5 mg subcutaneously once weekly after at least 4 weeks at 5 mg. Step 3: Increase to 10 mg subcutaneously once weekly after at least 4 weeks at 7.5 mg, if glycemic targets are not met. Step 4: Increase to 12.5 mg subcutaneously once weekly after at least 4 weeks at 10 mg. Step 5 (Maximum dose): Increase to 15 mg subcutaneously once weekly after at least 4 weeks at 12.5 mg; 15 mg is the maximum approved tirzepatide maintenance dose and is available in Tyzepa pre-filled syringes. Injection sites: Administer subcutaneously into the abdomen (at least 5 cm from the navel), thigh, or upper arm; rotate injection sites with each weekly dose to reduce local injection site reactions. Tyzepa may be injected at any time of day, with or without food. Missed dose: If a dose is missed and the next scheduled dose is more than 4 days away, administer the missed dose as soon as possible and resume the regular weekly schedule. If the next scheduled dose is 4 days or fewer away, skip the missed dose and continue with the next scheduled weekly injection. Do not administer two doses within 3 days of each other. Renal and hepatic impairment: No dose adjustment is required for mild to moderate renal impairment (eGFR 30 mL/min/1.73 m² or greater); use with caution in severe renal impairment. No dose adjustment is required for hepatic impairment. Always confirm the dose, injection technique, and escalation schedule with the prescribing endocrinologist before initiating or adjusting Tyzepa therapy.
Primary Indications Type 2 Diabetes Mellitus (T2DM): As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, used as monotherapy or in combination with other antidiabetic agents (metformin, sulfonylurea, SGLT2 inhibitor) or basal insulin when existing therapy does not achieve adequate glycemic control. Tirzepatide is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. Each treatment decision must account for baseline HbA1c, body weight goals, cardiovascular risk, concomitant antidiabetic medications, renal function, and gastrointestinal tolerability. Always consult the full prescribing information and the treating endocrinologist or diabetologist before initiating or adjusting Tyzepa therapy.
Manufacturer Drug International Ltd., Bangladesh
Country of Origin Bangladesh
SKU tirzepatide-tyzepa
Categories Diabetes Medicines; Tirzepatide Medicines
Registration Bangladesh
Originator Reference Brand Mounjaro® (tirzepatide injection, developed and marketed by Eli Lilly and Company; approved by the U.S. Food and Drug Administration on May 13, 2022, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus). Mounjaro® contains tirzepatide INN as the active pharmaceutical ingredient in the same dual GIP/GLP-1 receptor agonist (twincretin) drug class. Tyzepa is manufactured by Drug International Ltd. in Bangladesh and is supplied through Mediaid Pharmacy for international procurement.
Storage Conditions Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze; discard Tyzepa pre-filled syringes that have been frozen. If necessary, each pre-filled syringe may be stored unrefrigerated at room temperature up to 30°C (86°F) for a maximum of 21 days. Protect from light and direct heat. Keep in the original packaging until use. Keep out of the reach of children. Do not use after the expiry date printed on the carton and pre-filled syringe label.
Global Supplier Mediaid Pharmacy, Worldwide Shipping Available

How Tyzepa (Tirzepatide) Works: Dual GIP and GLP-1 Receptor Agonism and Twincretin Pharmacology in Type 2 Diabetes

Tirzepatide INN is a 39-amino acid acylated peptide that functions as a dual agonist at two distinct incretin hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). This dual receptor mechanism  the first of its kind among approved antidiabetic agents  earns tirzepatide the designation “twincretin.” Tyzepa (Tirzepatide) simultaneously activates two complementary glucose-lowering and weight-reducing signaling pathways that monoagonist GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide) cannot replicate within a single injection.

GLP-1 is secreted by intestinal L cells in the distal ileum and colon following nutrient ingestion, stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon secretion from pancreatic alpha cells, slowing gastric emptying to reduce postprandial glucose excursions, and activating hypothalamic and brainstem satiety circuits. GIP is secreted by K cells in the duodenum and proximal jejunum in response to fat and carbohydrate ingestion, potentiating glucose-dependent insulin secretion through a distinct cAMP signaling cascade in pancreatic beta cells and engaging adipose tissue GIPR-expressing cells involved in lipid partitioning and energy balance. In type 2 diabetes mellitus (T2DM), both incretin axes are functionally impaired: the GLP-1 response is markedly attenuated and the residual GIP response fails to elicit a normal insulin secretory response in the insulin-resistant beta cell. This is precisely the dual incretin deficit that tirzepatide’s co-receptor engagement addresses by simultaneously reconstituting both GIP and GLP-1 signaling arms within a single molecular entity administered once weekly.

The structural basis of tirzepatide’s dual receptor activity lies in its peptide architecture: a 39-amino acid sequence with structural homology to native GIP at the N-terminus, optimized through amino acid substitutions for balanced GIPR and GLP-1R binding affinity, conjugated at lysine-26 to a C20 fatty diacid moiety via a gamma-glutamic acid-miniPEG linker. This modification confers high albumin binding exceeding 99%, protects the peptide from N-terminal DPP-4 cleavage that inactivates native GIP and GLP-1 within 1 to 2 minutes of portal entry, and provides an extended elimination half-life of approximately 5 days that supports once-weekly subcutaneous dosing from the 2.5 mg initiation step through each sequential escalation step  5 mg, 7.5 mg, 10 mg, 12.5 mg, and the 15 mg maximum dose  all of which are available as separate procurable units in Tyzepa pre-filled syringes from Drug International Ltd.

Tirzepatide activates GIPR with potency approximately equivalent to native GIP and activates GLP-1R with approximately 5-fold lower potency than native GLP-1, yet produces GLP-1R-mediated pharmacological effects (insulin secretion, glucagon suppression, gastric emptying delay, appetite suppression, body weight reduction) that equal or exceed those of optimized GLP-1 monoagonists in head-to-head clinical trials. These superior outcomes are driven by receptor co-stimulation synergy, adipose tissue GIPR contributions to energy balance, and tissue-level interactions between the two simultaneously activated signaling pathways.

Pharmacokinetically, following subcutaneous administration via the pre-filled syringe, tirzepatide reaches peak plasma concentration (Tmax) at approximately 8 to 72 hours post-injection, achieves steady-state concentrations by 4 weeks of once-weekly dosing, and is eliminated primarily via proteolytic degradation of the peptide backbone and fatty acid beta-oxidation, with no single dominant cytochrome P450 (CYP) metabolic pathway and no clinically relevant accumulation with weekly dosing across a broad range of renal and hepatic function. The six-step dose titration architecture of Tyzepa (2.5 mg initiation → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg maximum dose) allows the prescribing endocrinologist to individually optimize the balance between glycemic efficacy, weight-reduction benefit, and gastrointestinal tolerability for each patient at every stage of the escalation ladder, without requiring a product switch or formulation change at any dose step. For the complete range of diabetes medicines at Mediaid Pharmacy, browse the full portfolio available for worldwide shipping.

Tyzepa (Tirzepatide): Indications, Dosing, and Key Safety Information

Approved Indications Type 2 Diabetes Mellitus (T2DM): Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Tyzepa (Tirzepatide) is used as monotherapy when other oral agents are not tolerated or are contraindicated, and as add-on combination therapy with metformin, sulfonylureas, SGLT2 inhibitors, or basal insulin when single-agent or existing combination therapy fails to achieve adequate HbA1c targets. Tirzepatide is not indicated for type 1 diabetes mellitus or diabetic ketoacidosis. The treating endocrinologist determines appropriate candidacy, dose titration schedule across the six dose steps (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg), and combination regimen based on individual patient HbA1c targets, weight goals, cardiovascular risk, renal function, and gastrointestinal tolerability profile.
Dosing Schedule Weeks 1–4 (Initiation): 2.5 mg subcutaneously once weekly  tolerability initiation dose, not the therapeutic maintenance dose.
Week 5 onward (Step 1 Therapeutic): 5 mg subcutaneously once weekly.
After ≥4 weeks at 5 mg (Step 2, if needed): 7.5 mg subcutaneously once weekly.
After ≥4 weeks at 7.5 mg (Step 3, if needed): 10 mg subcutaneously once weekly.
After ≥4 weeks at 10 mg (Step 4, if needed): 12.5 mg subcutaneously once weekly.
After ≥4 weeks at 12.5 mg (Step 5  Maximum Dose): 15 mg subcutaneously once weekly; 15 mg is the highest approved tirzepatide maintenance dose and is available in Tyzepa pre-filled syringes from Drug International Ltd.
Inject subcutaneously into the abdomen, thigh, or upper arm; rotate injection sites each week. Administer at any time of day, with or without meals.
Common Adverse Reactions The most commonly reported adverse reactions with tirzepatide in the SURPASS Phase 3 clinical trial program are gastrointestinal: nausea (12 to 18% at 5 mg, increasing modestly with dose escalation to higher dose steps), diarrhea (12 to 17%), vomiting (5 to 11%), and constipation (6 to 11%), predominantly occurring during dose initiation and escalation phases and generally transient in nature. The 2.5 mg initiation dose protocol across the first 4 weeks of Tyzepa therapy is specifically designed to reduce the frequency and severity of these gastrointestinal effects before advancing to the 5 mg therapeutic dose and subsequent escalation steps. Injection site reactions (erythema, pain, bruising) are reported in approximately 3 to 7% of patients; weekly site rotation minimizes their incidence. Hypoglycemia does not occur with Tyzepa as monotherapy due to its strictly glucose-dependent insulin secretion mechanism; hypoglycemia risk increases when tirzepatide is combined with a sulfonylurea or basal insulin, and dose reduction of the sulfonylurea or insulin should be considered at initiation. Rare serious adverse reactions include acute pancreatitis (discontinue Tyzepa immediately if suspected), severe hypersensitivity reactions including anaphylaxis and angioedema, and acute gallbladder disease (cholelithiasis, cholecystitis). Tyzepa (Tirzepatide) carries a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity data; it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Always discuss the complete safety profile with the treating endocrinologist before initiating or continuing Tyzepa therapy.
Drug Interactions Oral medications requiring rapid absorption or with narrow therapeutic index: Tirzepatide delays gastric emptying and may reduce the peak plasma concentration (Cmax) and alter the time to peak concentration (Tmax) of concomitantly administered oral medications. Particular caution is warranted with narrow therapeutic index oral drugs such as warfarin, cyclosporine, and digoxin. Oral contraceptives: When initiating Tyzepa or escalating the dose at any step, gastric emptying delay may transiently reduce peak concentrations of oral contraceptives; switch to non-oral contraception or add a barrier method for 4 weeks after starting Tyzepa and for 4 weeks after each dose escalation step. Warfarin and other vitamin K antagonists: Monitor INR more frequently when initiating or dose-escalating Tyzepa due to the potential effect on warfarin absorption kinetics. Insulin secretagogues and basal insulin: Concomitant use with a sulfonylurea (glimepiride, glibenclamide) or basal insulin (insulin glargine, insulin detemir) increases hypoglycemia risk; consider reducing the sulfonylurea or insulin dose when adding Tyzepa to existing antidiabetic therapy. Other GLP-1 receptor agonists: Do not combine Tyzepa (Tirzepatide) with another GLP-1 receptor agonist (semaglutide, liraglutide, dulaglutide, exenatide) as additive receptor agonism provides no established additional glycemic benefit and compounds gastrointestinal adverse effects.
Contraindications Tyzepa (Tirzepatide) is contraindicated in: patients with a personal or family history of medullary thyroid carcinoma (MTC); patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); patients with known serious hypersensitivity to tirzepatide or any component of the Tyzepa formulation (including anaphylaxis or angioedema). Tirzepatide is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.
Renal Impairment No dose adjustment of Tyzepa (Tirzepatide) is required for mild to moderate renal impairment (eGFR 30 mL/min/1.73 m² or greater). Use with caution in severe renal impairment (eGFR less than 30 mL/min/1.73 m²) due to limited clinical data; gastrointestinal adverse effects (nausea, vomiting, diarrhea) that occur particularly during the early dose escalation phase may precipitate dehydration and acute kidney injury in renally vulnerable patients, necessitating closer clinical monitoring, hydration counseling, and renal function assessment. Consult the treating endocrinologist and nephrologist for individualized guidance in patients with advanced chronic kidney disease before initiating or escalating Tyzepa.
Pregnancy & Lactation Tyzepa (Tirzepatide) is not recommended during pregnancy. Tirzepatide caused adverse embryo-fetal developmental effects in animal reproductive toxicity studies at clinically relevant exposures; adequate and well-controlled human data in pregnancy are not available. The risks of uncontrolled maternal hyperglycemia during pregnancy and of tirzepatide fetal exposure must be carefully weighed; insulin remains the preferred antidiabetic agent during pregnancy for type 2 diabetes mellitus. Women of childbearing potential should use effective contraception throughout Tyzepa therapy; if pregnancy occurs or is planned, discontinue Tyzepa and transition to insulin therapy immediately under endocrinologist guidance. Breastfeeding is not recommended during Tyzepa treatment, as it is unknown whether tirzepatide is excreted in human breast milk; the risk to the nursing infant cannot be excluded.

Who Should Use Tyzepa (Tirzepatide)?

Tyzepa (Tirzepatide) is indicated for adults with type 2 diabetes mellitus requiring improved glycemic control as an adjunct to diet and exercise, a patient population defined by progressive insulin secretory failure, marked GLP-1 and GIP response impairment, postprandial glucagon excess, and frequently co-occurring excess body weight, for whom a once-weekly dual incretin receptor agonist with a complete six-step dose titration architecture provides simultaneous glycemic and cardiometabolic benefits that are mechanistically unachievable by existing oral antidiabetic classes or monoagonist injectable agents.

First, adults with type 2 diabetes requiring substantial HbA1c reduction represent the primary population where Tyzepa’s superior efficacy profile is most clinically relevant. Those presenting with baseline HbA1c above 8.5%, or requiring reductions exceeding 1.5% to reach individual targets, benefit from the twincretin approach combined with Tyzepa’s stepwise escalation from 5 mg through 10 mg, 12.5 mg, and the 15 mg maximum dose  the only tirzepatide product range covering all six approved dose steps in a single procurable range. In SURPASS-1 monotherapy (40 weeks, 478 patients), tirzepatide 5 mg achieved 1.87% HbA1c reduction with 87.4% of patients reaching HbA1c below 7.0% versus 0.04% reduction and 19.9% target achievement with placebo. Dose escalation to 10 mg and 15 mg in SURPASS-2 produced HbA1c reductions of 2.01% and 2.30% respectively, the highest reductions reported for any approved antidiabetic agent in prospective trials.

Second, adults with type 2 diabetes and significant overweight or obesity for whom concurrent meaningful weight loss is a clinical priority represent an especially important population for Tyzepa therapy. In SURPASS-2 versus semaglutide 1 mg (40 weeks), tirzepatide at the 15 mg dose produced mean body weight reduction of 12.4 kg versus 5.7 kg with semaglutide 1 mg (p<0.001); the availability of the 10 mg, 12.5 mg, and 15 mg dose steps in Tyzepa means clinicians can titrate to the weight-reduction response required for each individual patient.

Third, adults with type 2 diabetes requiring injectable antidiabetic therapy escalation beyond the 5 mg or 7.5 mg dose steps available in other tirzepatide products benefit specifically from Tyzepa’s unique offering of the complete dose range through 15 mg within the same product line, eliminating the need for a product switch mid-escalation.

Fourth, adults with type 2 diabetes for whom minimizing hypoglycemia risk is a clinical priority benefit from tirzepatide’s glucose-dependent, insulin-only-when-needed mechanism, which produced no hypoglycemia as monotherapy across all SURPASS studies regardless of dose. Endocrinology centers and diabetes specialist clinics co-sourcing Tyzepa alongside other specialty injectable antidiabetic medicines can browse the Mediaid Pharmacy injectable diabetes medicines portfolio for the full selection available for international delivery.

Global Supplier: Mediaid Pharmacy Worldwide Shipping for Tyzepa (Tirzepatide)

Mediaid Pharmacy is a Dhaka-based supplier of specialty diabetes, endocrinology, and metabolic medicines with worldwide shipping to patients, diabetes specialist centers, endocrinology clinics, hospital pharmacy departments, and international distributors across all regions. Tyzepa (Tirzepatide), manufactured by Drug International Ltd. in Bangladesh, is supplied as a subcutaneous injection in pre-filled syringes, available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg strengths  the complete approved tirzepatide dose escalation range  with 1 pre-filled syringe per box, with pricing quotations, stock confirmation for each strength, full product documentation, and end-to-end international delivery tracking for every order. The pre-filled syringe formulation of Tyzepa supports once-weekly self-administration without requiring dose measurement or device assembly, making procurement, dispensing, patient instruction, and injection technique training straightforward for diabetes clinics and endocrinology programs co-sourcing all six dose steps across a single product range from a single supplier.

Diabetes specialist centers managing type 2 diabetes requiring superior glycemic and weight-reduction efficacy across the complete six-step dose escalation pathway, endocrinology programs requiring a dual GIP/GLP-1 receptor agonist tirzepatide injection with the full SURPASS Phase 3 clinical evidence base including 10 mg and 15 mg dose data, hospital pharmacy departments co-sourcing injectable antidiabetic agents for inpatient or outpatient use, international distributors, and individual patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all inquiries regarding Tyzepa Tirzepatide stock availability, current per-strength pricing, and international delivery timelines. Procurement teams co-sourcing Tyzepa with other specialty diabetes or metabolic medicines can browse the complete Mediaid Pharmacy buy diabetes medicines online catalog before requesting a consolidated quotation.

Why Choose Tyzepa (Tirzepatide) from Mediaid Pharmacy?

Tyzepa (Tirzepatide) delivers the most clinically documented HbA1c reduction and body weight reduction among approved injectable antidiabetic agents, a differentiation established in the SURPASS clinical trial program through a unique twincretin mechanism of simultaneous GIP and GLP-1 receptor co-activation that no single-receptor GLP-1 agonist, DPP-4 inhibitor, SGLT2 inhibitor, or insulin class member can replicate in a single weekly injection. In SURPASS-2 (1,879 adults with type 2 diabetes, 40 weeks), all tirzepatide doses demonstrated statistically significant superiority over semaglutide 1 mg in both HbA1c reduction and body weight reduction (p<0.001 for both endpoints), and at the 15 mg maximum dose tirzepatide achieved a mean HbA1c reduction of 2.30% and body weight reduction of 12.4 kg  outcomes unmatched by any approved antidiabetic agent studied in a prospective, randomized, active-controlled head-to-head trial.

Tyzepa’s defining procurement advantage is its complete six-strength range (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg), which covers every step of the approved tirzepatide dose escalation ladder from tolerability initiation through the maximum approved maintenance dose without requiring the prescriber to switch products or formulations at any escalation step. This is a clinically meaningful and logistically significant advantage: diabetes centers managing patients through the full titration sequence from 2.5 mg initiation to 15 mg maximum dose can source the entire escalation pathway from a single product under a single procurement agreement with Mediaid Pharmacy.

From a tolerability architecture perspective, the mandatory 2.5 mg initiation dose embedded in the approved dosing schedule reduces gastrointestinal adverse event-related treatment discontinuation during the first four weeks, with the added benefit that all six doses of Tyzepa are procurable from the same product range.

The absence of hypoglycemia as monotherapy, a direct consequence of tirzepatide’s strictly glucose-dependent insulin secretion mechanism, means Tyzepa can be initiated across the full escalation sequence (2.5 mg through 15 mg) without hypoglycemia dietary restriction protocols beyond standard diabetic care, clinically differentiating it from sulfonylureas and insulin.

From a dosing convenience standpoint, the once-weekly subcutaneous injection via the pre-filled syringe eliminates the daily injection burden of liraglutide and the daily oral medication adherence requirement of DPP-4 inhibitors and SGLT2 inhibitors, supporting high adherence profiles across the dose escalation period.

Tyzepa, manufactured by Drug International Ltd. in Bangladesh, delivers the same active pharmaceutical ingredient, tirzepatide INN, in pre-filled syringes at all approved subcutaneous injection formulation strengths, sourced through Mediaid Pharmacy with worldwide shipping. To source the complete range of Tyzepa Tirzepatide subcutaneous injection products at Mediaid Pharmacy and browse the broader portfolio of diabetes medicines available with worldwide shipping, contact the team for a personalized quotation.

Frequently Asked Questions About Tyzepa (Tirzepatide)

What is Tyzepa (Tirzepatide) used for?

Tyzepa (Tirzepatide) is a dual GIP and GLP-1 receptor agonist  a twincretin  used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Administered once weekly as a subcutaneous injection via a pre-filled syringe, Tyzepa is used as monotherapy when metformin or other oral agents are not tolerated or are contraindicated, and as add-on combination therapy with metformin, sulfonylureas, SGLT2 inhibitors, or basal insulin when existing treatment fails to achieve adequate HbA1c control. Tyzepa (Tirzepatide) works by simultaneously activating the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R), stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing inappropriate glucagon release, slowing gastric emptying to reduce postprandial glucose excursions, and engaging central satiety pathways to reduce appetite and body weight, producing clinically superior HbA1c and body weight reductions compared to monoagonist GLP-1 receptor agonists in head-to-head prospective trials. The originator brand for tirzepatide is Mounjaro® (Eli Lilly and Company, FDA-approved May 13, 2022 for adults with T2DM). Tyzepa, manufactured by Drug International Ltd. in Bangladesh, is available through Mediaid Pharmacy with worldwide shipping to patients, diabetes specialist centers, and endocrinology clinics globally.

What is the generic name of Tyzepa?

The generic name of Tyzepa is tirzepatide INN. Tyzepa is the brand name registered by Drug International Ltd. for tirzepatide manufactured in Bangladesh. Tyzepa is formulated as a subcutaneous injection in pre-filled syringes, available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg strengths  the complete six-step approved escalation range  supplied as 1 pre-filled syringe per box, supporting the approved once-weekly dosing schedule from initiation at 2.5 mg through stepwise dose escalation to the 15 mg maximum dose as directed by the treating endocrinologist. The originator reference brand is Mounjaro® (Eli Lilly and Company). Mediaid Pharmacy distributes Tyzepa globally with worldwide shipping to patients, diabetes centers, endocrinology clinics, and hospital pharmacy departments.

What is the difference between Tyzepa (Tirzepatide) and Mounjaro® (Tirzepatide)?

Tyzepa and Mounjaro® both contain tirzepatide INN as the active pharmaceutical ingredient and share the same dual GIP/GLP-1 receptor agonist (twincretin) mechanism of action for type 2 diabetes mellitus. Mounjaro® is the originator brand developed and marketed by Eli Lilly and Company, approved by the FDA on May 13, 2022, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Tyzepa is manufactured by Drug International Ltd. in Bangladesh and is supplied in pre-filled syringes in all six approved strengths  2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg  covering the complete tirzepatide escalation schedule from tolerability initiation through the maximum maintenance dose, with 1 pre-filled syringe per box, available through Mediaid Pharmacy for international procurement by specialist diabetes centers and patients in regions where Mounjaro® may be unavailable or cost-prohibitive. For the full range of tirzepatide injection products at Mediaid Pharmacy, browse the complete collection.

How is Tyzepa (Tirzepatide) administered?

Tyzepa (Tirzepatide) is administered once weekly as a subcutaneous injection using the pre-filled syringe. Recommended injection sites are the abdomen (at least 5 cm from the navel), the thigh, or the upper arm; rotate injection sites with each weekly administration to minimize local injection site reactions such as erythema, bruising, and pain. Tyzepa may be administered at any time of day, independently of meals. The approved initiation schedule begins with 2.5 mg once weekly for 4 weeks; after 4 weeks, advance to 5 mg once weekly. If additional glycemic control is required after at least 4 weeks at 5 mg, increase to 7.5 mg; then to 10 mg, 12.5 mg, and finally 15 mg (maximum dose), each after a minimum of 4 weeks at the preceding dose step. If a dose is missed and the next scheduled dose is more than 4 days away, administer the missed dose as soon as possible and resume the regular weekly schedule. If the next scheduled dose is 4 days or fewer away, skip the missed dose and continue with the next scheduled weekly injection; never administer two doses within 3 days of each other. Store Tyzepa pre-filled syringes refrigerated at 2°C to 8°C until use. Always confirm injection technique and dose escalation timing with the prescribing endocrinologist before commencing Tyzepa therapy.

What are the side effects of Tyzepa (Tirzepatide)?

The most common side effects of Tyzepa (Tirzepatide) are gastrointestinal: nausea (reported in 12 to 18% of patients at 5 mg, with modest increase at higher dose steps), diarrhea (12 to 17%), vomiting (5 to 11%), and constipation (6 to 11%), predominantly occurring during dose initiation and escalation and typically transient. The mandatory 2.5 mg initiation dose protocol for the first 4 weeks is specifically designed to reduce the frequency and severity of gastrointestinal adverse effects before advancing to the 5 mg and subsequent therapeutic doses. Injection site reactions (erythema, bruising, pain at the injection site) are reported in approximately 3 to 7% of patients; rotating injection sites each week reduces their incidence. Hypoglycemia does not occur with Tyzepa as monotherapy due to its glucose-dependent insulin secretion mechanism; hypoglycemia risk increases when Tyzepa is combined with a sulfonylurea or basal insulin, and dose reduction of those agents should be considered. Rare but serious adverse reactions include acute pancreatitis (discontinue Tyzepa immediately if pancreatitis is suspected) and severe hypersensitivity reactions including anaphylaxis and angioedema. Tyzepa carries a boxed warning for thyroid C-cell tumors (medullary thyroid carcinoma observed in rodent studies at clinically relevant exposures); instruct patients to report any neck masses, hoarseness, dysphagia, or persistent dysphonia. Always discuss the full safety profile, thyroid carcinoma family history, contraindications, and combination therapy hypoglycemia risk with the treating endocrinologist before and throughout Tyzepa treatment.

Does Tyzepa (Tirzepatide) cause weight loss?

Yes. Tyzepa (Tirzepatide) produces clinically meaningful and dose-dependent body weight reductions in adults with type 2 diabetes, driven by its dual GIP and GLP-1 receptor agonism acting on hypothalamic satiety circuits to reduce appetite, gastric emptying delay reducing caloric absorption rate, and adipose tissue GIPR engagement modulating energy partitioning. In SURPASS-1 monotherapy (40 weeks), tirzepatide 5 mg produced mean body weight reduction of 7.0 kg versus 0.7 kg with placebo. The higher dose steps available in Tyzepa (10 mg, 12.5 mg, 15 mg) deliver progressively greater weight reductions: the 15 mg maximum dose produced mean weight loss of 12.4 kg in SURPASS-2 versus semaglutide 1 mg (40 weeks, 1,879 patients), significantly greater than semaglutide 1 mg at 5.7 kg (p<0.001), accompanied by improvements in waist circumference, systolic blood pressure, triglycerides, and markers of insulin resistance. The availability of the complete dose range in Tyzepa  from 5 mg through 15 mg  allows the treating endocrinologist to titrate to the weight-reduction and glycemic response the patient requires. For the full range of diabetes medicines at Mediaid Pharmacy available with worldwide shipping, browse the complete portfolio.

How does Tyzepa (Tirzepatide) compare to semaglutide for type 2 diabetes?

Tyzepa (Tirzepatide) and semaglutide (originator brand: Ozempic®) are both once-weekly subcutaneous injectable antidiabetic agents, but they act through different receptor mechanisms. Semaglutide is a monoagonist GLP-1 receptor agonist that activates only the GLP-1R. Tirzepatide is a dual GIP/GLP-1 receptor agonist (twincretin) that simultaneously activates both the GIPR and GLP-1R, adding an incretin signaling arm that semaglutide does not engage. In the SURPASS-2 head-to-head trial (1,879 adults with T2DM, 40 weeks), tirzepatide at all doses studied demonstrated statistically significant superiority over semaglutide 1 mg in both HbA1c reduction and body weight reduction (p<0.001 for both endpoints); at the 15 mg maximum dose available in Tyzepa, tirzepatide achieved 2.30% HbA1c reduction and 12.4 kg weight loss versus 1.86% and 5.7 kg with semaglutide 1 mg. This superiority across all doses of tirzepatide versus the most widely prescribed GLP-1 receptor agonist in a randomized, active-controlled trial is the defining clinical differentiation of the twincretin class. The full selection of tirzepatide medicines at Mediaid Pharmacy is available for worldwide shipping; contact the team for per-strength pricing and current stock availability.

What are the available strengths of Tyzepa Tirzepatide?

Tyzepa (Tirzepatide) manufactured by Drug International Ltd. is available in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg pre-filled syringes, supplied as 1 pre-filled syringe per box. This is the complete approved tirzepatide dose escalation range. The 2.5 mg strength covers the 4-week tolerability initiation phase; the 5 mg strength is the first therapeutic maintenance dose; and the 7.5 mg, 10 mg, 12.5 mg, and 15 mg strengths represent the sequential dose intensification steps for patients requiring additional glycemic control and body weight reduction, with 15 mg being the maximum approved tirzepatide dose. All six dose steps are available as separate procurable units from Mediaid Pharmacy, enabling diabetes specialist centers to manage patients through the full escalation pathway from a single product range. For ordering, stock confirmation by strength, and current pricing, contact Mediaid Pharmacy at +8801773428128 or email info@mediaidpharmacy.com.

Who manufactures Tyzepa Tirzepatide?

Tyzepa (Tirzepatide) is manufactured by Drug International Ltd., a pharmaceutical company based in Bangladesh. Drug International Ltd. produces Tyzepa as a subcutaneous injection in pre-filled syringes in all six approved tirzepatide dose strengths  2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg  containing tirzepatide INN as the active pharmaceutical ingredient. Mediaid Pharmacy, a Dhaka-based specialty medicine supplier, distributes Tyzepa by Drug International Ltd. globally with worldwide shipping. The originator reference brand for tirzepatide is Mounjaro® (Eli Lilly and Company, USA). Tyzepa provides the same dual GIP/GLP-1 receptor agonist (twincretin) active ingredient as the originator across the complete dose range.

Can I order Tyzepa (Tirzepatide) online with worldwide shipping?

Yes. Mediaid Pharmacy supplies Drug International Ltd. Tyzepa (Tirzepatide) pre-filled syringes in all six strengths  2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg  to patients, diabetes specialist centers, endocrinology clinics, hospital pharmacy departments, and healthcare providers globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com for pricing by strength, current stock availability, and international delivery details for your country. Browse the complete tirzepatide subcutaneous injection range at Mediaid Pharmacy to confirm all available strengths before placing an order.

Order Tyzepa (Tirzepatide) with Worldwide Shipping

Phone / WhatsApp / WeChat: +8801773428128  |  Email: info@mediaidpharmacy.com

Message on WhatsApp

Reviews

There are no reviews yet.

Be the first to review “Tyzepa (Tirzepatide)”

Your email address will not be published. Required fields are marked *